Remission of Human Type 2 Diabetes Requires Decrease in Liver and Pancreas Fat Content but Is Dependent upon Capacity for \( \beta \) Cell Recovery

**Highlights**

- Substantial weight loss can reverse the processes underlying type 2 diabetes
- Liver fat content is normalized and pancreas fat content decreased in all
- Return to non-diabetic glucose control depends upon \( \beta \) cell ability to recover

**Authors**

Roy Taylor, Ahmad Al-Mrabehe, Sviatlana Zhyzhneuskaya, ..., John C. Mathers, Naveed Sattar, Michael E.J. Lean

**Correspondence**

roy.taylor@ncl.ac.uk

**In Brief**

Type 2 diabetes has long been regarded as lifelong and progressive. Taylor et al. demonstrate that weight loss of over 10 kg results in normalization of ectopic fat within liver and pancreas. This is associated with durable recovery of \( \beta \) cell function and non-diabetic glucose control in the majority.
Remission of Human Type 2 Diabetes Requires Decrease in Liver and Pancreas Fat Content but Is Dependent upon Capacity for β Cell Recovery

Roy Taylor,1,7,∗ Ahmad Al-Mrabeh,1 Sviatlana Zhyzhneuskaya,1 Carl Peters,1 Alison C. Barnes,2 Benjamin S. Arbisala,3 Kieren G. Hollingsworth,1 John C. Mathers,4 Naveed Sattar,5 and Michael E.J. Lean6

1Newcastle Magnetic Resonance Centre, Institute of Cellular Medicine, Newcastle University, Campus for Ageing & Vitality, Newcastle upon Tyne NE4 5PL, UK
2Human Nutrition Research Centre, Institute of Health & Society, Newcastle University, Newcastle upon Tyne NE2 4HH, UK
3Department of Computer Science, Lagos State University, Ojo, Lagos State, Nigeria
4Human Nutrition Research Centre, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne NE2 4HH, UK
5Institute of Cardiovascular and Medical Science, University of Glasgow, Glasgow G12 8TA, UK
6Human Nutrition, School of Medicine, Dentistry and Nursing, College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow G31 2ER, UK
7Lead Contact
∗Correspondence: roy.taylor@ncl.ac.uk
https://doi.org/10.1016/j.cmet.2018.07.003

SUMMARY

The Diabetes Remission Clinical Trial reported return and persistence of non-diabetic blood glucose control in 46% of people with type 2 diabetes of up to 6 years duration. Detailed metabolic studies were performed on a subgroup (intervention, n = 64; control, n = 26). In the intervention group, liver fat content decreased (16.0% ± 1.3% to 3.1% ± 0.5%, p < 0.0001) immediately after weight loss. Similarly, plasma triglyceride and pancreas fat content decreased whether or not glucose control normalized. Recovery of first-phase insulin response (0.04[−0.05–0.32] to 0.11[0.0005–0.51] nmol/min/m², p < 0.0001) defined those who returned to non-diabetic glucose control and this was durable at 12 months (0.11[0.0005–0.81] nmol/min/m², p = 0.0001). Responders were similar to non-responders at baseline but had shorter diabetes duration (2.7 ± 0.3 versus 3.8 ± 0.4 years; p = 0.02). This study demonstrates that β cell ability to recover long-term function persists after diagnosis, changing the previous paradigm of irreversible loss of β cell function in type 2 diabetes.

INTRODUCTION

Type 2 diabetes now affects at least one in ten US adults, and 422 million worldwide (Menke et al., 2015; WHO, 2016). It has long been regarded as an inevitably progressive, lifelong condition. However, the Diabetes Remission Clinical Trial (DiRECT) has demonstrated that nearly half of those with early (<6 years) type 2 diabetes can be returned to long-term non-diabetic glucose control using an effective method to achieve and maintain substantial weight loss (Lean et al., 2017). The initial period of weight loss was followed by weight maintenance and the data were reported at 12 months. This population-based study built upon the results of earlier small studies that revealed the detailed physiological basis of the transition from type 2 diabetes to normal (Lim et al., 2011; Petersen et al., 2005; Steven et al., 2016a, 2016b). However, whether these mechanisms operate in all individuals with type 2 diabetes and the critical factor(s) that determine the capacity to return to non-diabetic glucose metabolism remain uncertain.

During a very low-calorie diet in type 2 diabetes, an initial study showed that liver fat content rapidly decreased, with normalization of hepatic insulin sensitivity within 7 days (Lim et al., 2011). Over an 8-week period, pancreas fat content decreased more slowly, as first-phase insulin response gradually returned. A follow-up study demonstrated that, as duration of type 2 diabetes increased beyond 10 years, the possibility of restoring β cell function decreased (Steven et al., 2016a). These observations led to a simplified view of the etiology of type 2 diabetes (Taylor, 2013), consistent with earlier observations (Henry et al., 1986; Wing et al., 1987), in that linked but distinct mechanisms in liver and pancreas appeared to explain the condition. Recently, the molecular basis of the liver abnormalities in type 2 diabetes has been clarified (Perry et al., 2018). In addition, a major decline in β cell function is necessary before type 2 diabetes develops. In the last few years, metabolic stress-induced β cell de-differentiation and subsequent re-differentiation with significant weight loss have been demonstrated, potentially explaining any return from type 2 diabetes to normal glucose tolerance (Cinti et al., 2016; Pinnick et al., 2010; Talchai et al., 2012; White et al., 2016). A larger study was required to determine the extent to which this explains common type 2 diabetes.

Detailed pathophysiological studies were carried out in a geographically pre-defined subgroup of DiRECT participants (Figure 1). These were designed to test the hypothesis that there would be differences between those who did or did not return to non-diabetic glucose control in some or all of the factors previously identified as underlying type 2 diabetes. We have examined liver fat content, liver export of triglyceride, pancreas fat content, and β cell function in type 2 diabetes during
conventional therapy, after weight loss, and after 12 months of weight maintenance.

RESULTS AND DISCUSSION

Baseline Characteristics
Responders, who returned to non-diabetic glucose control after weight loss, and non-responders, who did not, were similar in age, weight, and sex (Table 1; Figure 3A). Responders had a non-significantly lower fasting plasma glucose than non-responders (148.9 ± 6.8 versus 167.8 ± 11.9 mg/dL, p = 0.18; Figure 3B), and HbA1c was 7.4% ± 0.2% versus 7.9% ± 0.2%, respectively (p = 0.04; Figure 3C). At baseline, liver fat in the whole intervention group was 16.0% ± 1.3% and was not significantly different in responders and non-responders (16.7% ± 1.5% versus 14.5% ± 2.6%, respectively, p = 0.47). There was no significant difference at baseline between responders and non-responders in VLDL1-TG production (560.7 ± 30.9 versus 581.1 ± 29.0 mg/kg/day, p = 0.74; Figure 4C) or total plasma triglyceride (1.8 ± 0.3 versus 1.9 ± 0.2 mmol/L, p = 0.76). The non-responders had a longer duration of diabetes (2.7 ± 0.3 versus 3.8 ± 0.4 years, p = 0.02), lower fasting plasma insulin (108.3 ± 10.0 versus 77.2 ± 8.5 pmol/L, p = 0.02) and lower plasma alanine aminotransferase (ALT) (34.1 ± 2.8 versus 26.3 ± 2.6 pmol/L, p < 0.05). Data on the whole intervention group compared with the conventionally treated control group are shown in Table S1.

Lower fasting plasma insulin levels and lower plasma ALT in individuals with type 2 diabetes who cannot achieve non-diabetic glucose control after weight loss have previously been observed in a group with up to 23 years duration of diabetes (Steven et al., 2016a). In that study, longer duration was clearly associated with inability to achieve remission. The increase in liver fat (1.5% ± 0.3% versus 2.8% ± 0.5%, p = 0.03, respectively, compared with post weight loss) was related to degree of weight gain. Those who gained less than the mean weight gain of the responder group (3.3 kg) had no change in liver fat (3.2% ± 1.1% versus 3.2% ± 1.0%, p = 0.95, n = 16). In contrast, in those who gained more than 3.3 kg, there was a resultant increase in liver fat (1.5% ± 0.3% versus 2.8% ± 0.5%, p = 0.03.

Liver Fat
Liver fat content decreased after weight loss in both groups (responders, to 3.3% ± 0.6%, p < 0.0001; non-responders, to 2.6% ± 0.5%, p < 0.0001; Figure 4A). The change in liver fat was similar (−13.4% ± 1.4% versus −11.9% ± 2.4%, p = 0.60; Table 2). At 12 months, liver fat in responders was 3.0% ± 0.6% and in non-responders 6.1% ± 1.9% (p = 0.11 and p = 0.04, respectively, compared with post weight loss). The increase in liver fat in the weight maintenance phase was related to degree of weight gain. Those who gained less than the mean weight gain of the responder group (3.3 kg) had no change in liver fat (3.2% ± 1.1% versus 3.2% ± 1.0%, p = 0.95, n = 16). In contrast, in those who gained more than 3.3 kg, there was a resultant increase in liver fat (1.5% ± 0.3% versus 2.8% ± 0.5%, p = 0.03,
be controlled. High-fat feeding of rodents brings about raised normal insulin action, and hepatic glucose production fails to raised level of intracellular diacylglycerol specifically prevents (Samuel et al., 2010). So under circumstances of chronic energy excess, a receptor step in intracellular insulin action (Samuel et al., 2004), and these changes have recently been shown to reverse after 3 days on a very low-calorie diet (Perry et al., 2018). Excess diacylglycerol has a pronounced effect in activating PKC-ζ, which inhibits the signaling pathway from the insulin receptor to IRS-1, the first post-receptor step in intracellular insulin action (Samuel et al., 2010). So under circumstances of chronic energy excess, a raised level of intracellular diacylglycerol specifically prevents normal insulin action, and hepatic glucose production fails to be controlled. High-fat feeding of rodents brings about raised levels of diacylglycerol, PKCζ activation, and insulin resistance (Samuel et al., 2004), and these changes have recently been shown to reverse after 3 days on a very low-calorie diet (Perry et al., 2018). The relationship between raised diacylglycerol, PKCζ activation, and hepatic insulin resistance leading to increased hepatic glucose output was clearly demonstrated in this recent study. In obese humans, intrahepatic diacylglycerol concentration has been shown to correlate with hepatic insulin sensitivity (Kumashiro et al., 2011; Magkos et al., 2012). It must be noted that raised diacylglycerol and PKCζ activation are corrected early during calorie restriction and before major weight change (Lim et al., 2011; Perry et al., 2018). This should not be interpreted to indicate that the more gradually occurring weight loss is not necessary for long-term normalization. The mechanisms underlying hepatic insulin resistance are now established, and the present observations demonstrate the complete reversibility of the liver abnormalities of human type 2 diabetes.

### Lipid Metabolism

In responders, VLDL1-TG production decreased after weight loss (to 413.6 ± 25.8 mg/kg/day, p < 0.0001; Figure 4C). In non-responders, there was a non-significant fall (to 521.8 ± 43.2 mg/kg/day, p = 0.28). The change during weight loss was not significantly different between responders and non-responders (−147.2 ± 33.8 versus −59.2 ± 52.7 mg/kg/day, p = 0.17). VLDL1-TG production rate did not change during the weight maintenance phase in responders (at 12 months, 437.5 ± 22.4 mg/kg/day, p = 0.12) but increased in non-responders (to 494.6 ± 57.0 mg/kg/day, p = 0.008).

Plasma VLDL1-TG concentration decreased in responders after weight loss (0.69 ± 0.07 to 0.44 ± 0.06 mmol/L, p = 0.001; Figure 4E), followed by a small increase during weight maintenance (to 0.49 ± 0.08 mmol/L, p = 0.04; Figure 4E). There was no significant change in non-responders after weight loss (0.73 ± 0.11 to 0.55 ± 0.12 mmol/L, p = 0.12) or during the weight maintenance phase (to 0.64 ± 0.12 mmol/L, p = 0.12).

Total plasma triglyceride (largely chylomicrons plus VLDL-TG) fell similarly in responders and non-responders after weight loss (1.84 ± 0.13 to 1.30 ± 0.13 mmol/L, p < 0.0001 and 1.91 ± 0.25 to 1.24 ± 0.14 mmol/L, respectively, p = 0.002; Figure 4B). This remained stable at 12 months (responders, to 1.24 ± 0.12 mmol/L, non-responders, to 1.28 ± 0.15 mmol/L).

### Table 1. Anthropometric, Clinical, and Metabolic Features of Responders and Non-responders before and after Intervention

<table>
<thead>
<tr>
<th></th>
<th>Responders (n = 40)</th>
<th>Non-responders (n = 40)</th>
<th>Baseline (n = 18)</th>
<th>Post Weight Loss (n = 18)</th>
<th>12 Months (n = 16)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BMI (kg/m²)</strong></td>
<td>34.9 ± 0.7</td>
<td>35.7 ± 1.2</td>
<td>34.1 ± 1.3</td>
<td>34.2 ± 1.4</td>
<td></td>
</tr>
<tr>
<td><strong>Age (year)</strong></td>
<td>53.0 ± 1.2</td>
<td>53.3 ± 1.9</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Sex (F/M)</strong></td>
<td>17/23</td>
<td>9/9</td>
<td>18/8</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Diabetes duration (years)</strong></td>
<td>2.7 ± 0.3</td>
<td>3.8 ± 0.4</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td><strong>VLDL1-TG pool (mg)</strong></td>
<td>2,445.9 ± 267</td>
<td>2,775.4 ± 505</td>
<td>1,866.4 ± 432</td>
<td>2,234.1 ± 570</td>
<td></td>
</tr>
<tr>
<td><strong>Fasting NEFA (mmol/L)</strong></td>
<td>0.56 ± 0.03</td>
<td>0.66 ± 0.04</td>
<td>0.59 ± 0.05</td>
<td>0.61 ± 0.04</td>
<td></td>
</tr>
<tr>
<td><strong>ALT (U/L)</strong></td>
<td>34.1 ± 2.8</td>
<td>26.3 ± 2.6</td>
<td>18.3 ± 2.0</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td><strong>Cholesterol (mmol/L)</strong></td>
<td>4.3 ± 0.2</td>
<td>4.1 ± 0.3</td>
<td>4.0 ± 0.2</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td><strong>HDL (mmol/L)</strong></td>
<td>1.09 ± 0.05</td>
<td>0.99 ± 0.05</td>
<td>1.11 ± 0.06</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td><strong>Ketone (mmol/L)</strong></td>
<td>0.19 ± 0.02</td>
<td>0.18 ± 0.02</td>
<td>0.20 ± 0.02</td>
<td>0.24 ± 0.04</td>
<td></td>
</tr>
<tr>
<td><strong>Lipid oxidation (mg/kg/min)</strong></td>
<td>0.96 ± 0.05</td>
<td>0.84 ± 0.08</td>
<td>0.89 ± 0.11</td>
<td>0.83 ± 0.07</td>
<td></td>
</tr>
<tr>
<td><strong>Glucose oxidation (mg/kg/min)</strong></td>
<td>1.27 ± 0.12</td>
<td>1.48 ± 0.17</td>
<td>1.31 ± 0.20</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td><strong>Resting energy expenditure (kcal/day)</strong></td>
<td>1,996.5 ± 57.0</td>
<td>1,981.7 ± 108.0</td>
<td>1,641.1 ± 89.5</td>
<td>1,733.2 ± 109.5</td>
<td></td>
</tr>
</tbody>
</table>

Paired data are presented (baseline to post weight loss or baseline/post weight loss to 12 months).

- p < 0.05 versus baseline
- p < 0.01 versus baseline
- p < 0.001 versus baseline
- p < 0.05 versus 5 months
- p < 0.01 versus 5 months
- p < 0.001 versus 5 months
- p < 0.05 responders versus non-responders

n = 12. In those randomized to the conventionally treated control group, there was no significant change in liver fat throughout the study (Figure 4A; Table S1). The importance of high levels of liver fat in the pathogenesis of type 2 diabetes is now recognized (Bril and Cusi, 2017; Petersen et al., 2005; Shibata et al., 2007; Steven et al., 2016b; Taylor, 2013). Raised liver fat levels are associated with hepatic insulin resistance, inadequate suppression of hepatic glucose production, and hence increased fasting plasma glucose (Petersen et al., 2005; Ravikumar et al., 2008; Seppala-Lindroos et al., 2002). Excess diacylglycerol has a profound effect in activating PKCζ, which inhibits the signaling pathway from the insulin receptor to IRS-1, the first post-receptor step in intracellular insulin action (Samuel et al., 2010). So under circumstances of chronic energy excess, a raised level of intracellular diacylglycerol specifically prevents normal insulin action, and hepatic glucose production fails to be controlled. High-fat feeding of rodents brings about raised levels of diacylglycerol, PKCζ activation, and insulin resistance (Samuel et al., 2004), and these changes have recently been shown to reverse after 3 days on a very low-calorie diet (Perry et al., 2018). The relationship between raised diacylglycerol, PKCζ activation, and hepatic insulin resistance leading to increased hepatic glucose output was clearly demonstrated in this recent study. In obese humans, intrahepatic diacylglycerol concentration has been shown to correlate with hepatic insulin sensitivity (Kumashiro et al., 2011; Magkos et al., 2012). It must be noted that raised diacylglycerol and PKCζ activation are corrected early during calorie restriction and before major weight change (Lim et al., 2011; Perry et al., 2018). This should...
p = 0.43; non-responders, to 1.39 ± 0.21 mmol/L, p = 0.52). In those randomized to control, there was no significant change in any parameter of lipid metabolism during the study (Table S1).

The series of studies that led to DiRECT was initiated to test the twin-cycle hypothesis (Taylor, 2008). This described vicious cycles within the liver and pancreas, respectively, ratcheting up hepatic insulin resistance and β cell dysfunction. Critically, it postulated that these cycles were linked by elevated insulin driving increased fatty acid uptake and increased hepatic VLDL1-TG export. The increased exposure of β cells to fat metabolites was postulated to lead ultimately to β cell failure. VLDL1-TG is a major determinant of plasma triglyceride (Hiukka et al., 2005). In non-obese individuals, this process accounts for only a small proportion of the fatty acids of de novo lipogenesis to VLDL1-TG; whereas in NAFLD it accounts for up to 26% (Adiels et al., 2006). The dramatic and sustained normalization of liver fat content in the present study was associated with a fall in both VLDL1-TG production and total plasma triglyceride—consistent with the predictions of the twin-cycle hypothesis.

### Pancreas Fat
Pancreas fat did not differ significantly between responders and non-responders at baseline (8.7% ± 0.4% versus 7.9% ± 0.6%, p = 0.25; Figure 4D). Weight loss produced a similar fall in intra-pancreatic fat in both groups (responders, to 7.8% ± 0.4%, p < 0.0001; non-responders, to 7.1% ± 0.5%, p = 0.004). There was no significant difference in extent of change between the two groups (−0.90% ± 0.17% versus −0.78% ± 0.23%, p = 0.43; non-responders, to 1.39 ± 0.21 mmol/L, p = 0.52). In those randomized to control, there was no significant change in any parameter of lipid metabolism during the study (Table S1).

### Table 2. Metabolic Changes in Responders and Non-responders during Weight Loss, during Weight Maintenance, and from Baseline to 12 Months

<table>
<thead>
<tr>
<th>Δ Change</th>
<th>Baseline to Post Weight Loss</th>
<th>Post Weight Loss to 12 Months</th>
<th>Baseline to 12 Months</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Responders (n = 40)</td>
<td>Non-responders (n = 18)</td>
<td>Responders (n = 29)</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>−16.2 ± 1.2</td>
<td>−13.4 ± 1.4</td>
<td>3.3 ± 0.8</td>
</tr>
<tr>
<td>Fasting plasma insulin</td>
<td>−46.6 ± 7.3</td>
<td>−8.9 ± 12.0</td>
<td>1.6 ± 2.6</td>
</tr>
<tr>
<td>HbA1c (%)</td>
<td>−1.5 ± 0.2</td>
<td>0.2 ± 0.4</td>
<td>−0.1 ± 0.5</td>
</tr>
<tr>
<td>Liver fat (%)</td>
<td>−13.4 ± 1.4</td>
<td>−11.9 ± 2.4</td>
<td>0.6 ± 0.3</td>
</tr>
<tr>
<td>VLDL1-TG production</td>
<td>−147.2 ± 33.8</td>
<td>−59.2 ± 52.7</td>
<td>43.1 ± 26.7</td>
</tr>
<tr>
<td>Plasma VLDL1-TG (mmol/L)</td>
<td>−0.26 ± 0.07</td>
<td>−0.19 ± 0.12</td>
<td>0.10 ± 0.05</td>
</tr>
<tr>
<td>VLDL1-TG pool (mg)</td>
<td>−1,187.5 ± 245.9</td>
<td>−909.0 ± 385.4</td>
<td>391.5 ± 149.0</td>
</tr>
<tr>
<td>Total plasma TG (mmol/L)</td>
<td>−0.54 ± 0.12</td>
<td>−0.67 ± 0.19</td>
<td>0.08 ± 0.10</td>
</tr>
<tr>
<td>Fasting plasma insulin</td>
<td>−69.7 ± 9.3</td>
<td>−41.7 ± 5.8</td>
<td>7.2 ± 3.9</td>
</tr>
<tr>
<td>Pancreas fat (%)</td>
<td>−0.90 ± 0.17</td>
<td>−0.78 ± 0.23</td>
<td>−0.14 ± 0.28</td>
</tr>
<tr>
<td>First-phase insulin</td>
<td>0.08 ± 0.02</td>
<td>−0.11 ± 0.06</td>
<td>0.02 ± 0.02</td>
</tr>
<tr>
<td></td>
<td>[−0.17–0.47]</td>
<td>[−0.11–0.06]</td>
<td>[−0.32–0.51]</td>
</tr>
<tr>
<td>Maximal insulin secretion</td>
<td>0.08 ± 0.03</td>
<td>0.08 ± 0.03</td>
<td>0.09 ± 0.03</td>
</tr>
<tr>
<td></td>
<td>[−1.37–2.66]</td>
<td>[−1.80–0.66]</td>
<td>[−2.17–1.81]</td>
</tr>
<tr>
<td>Glucose oxidation rate</td>
<td>0.17 ± 0.19</td>
<td>−0.29 ± 0.27</td>
<td>0.82 ± 0.22</td>
</tr>
<tr>
<td>Lipid oxidation rate</td>
<td>−0.09 ± 0.08</td>
<td>0.05 ± 0.13</td>
<td>0.31 ± 0.10</td>
</tr>
</tbody>
</table>

Paired data are used to present changes between different phases of the study.

* p < 0.05 responders versus non-responders

* * p < 0.01 responders versus non-responders

* * * p < 0.0001 responders versus non-responders

VLDL1-TG. This may possibly relate to different hepatic insulin sensitivity or plasma glucose levels in responders compared with non-responders. Although the major source of fatty acids supplying VLDL1-TG export is from adipose-derived fatty acids (around 60%), the contribution of de novo lipogenesis to VLDL1-TG is much greater when liver triglyceride levels are raised (Donnelly et al., 2005). In non-obese individuals, this process accounts for only a small proportion of the fatty acids of VLDL1-TG, whereas in NAFLD it accounts for up to 26% (Lambert et al., 2014; Timlin et al., 2005). The present observations on change in VLDL1-TG and total plasma triglyceride are consistent with the predictions of the twin-cycle hypothesis.
The magnetic resonance method quantifies fat content of both exocrine and endocrine pancreas, and the relationship of this to islet fat content and exposure must be considered. In rodents, β cell triglyceride content is directly related to total intrapancreatic fat content, and these parameters change in step (Lee et al., 2010).

In vivo measurement of intrapancreatic fat content in human studies during an 8-week period of calorie restriction in type 2 diabetic humans is concordant with the rodent observations, and also matches the gradual return of first-phase insulin secretion in that study (Lim et al., 2011). The change in total intrapancreatic fat is not seen during equivalent loss of weight in non-diabetic humans (Steven et al., 2016b), implying a specific excess of intracellular triglyceride within both exocrine and endocrine cells of the pancreas in type 2 diabetes. In addition to this endogenous pool, the ongoing exposure of β cells to excess fatty acid delivered from plasma VLDL1-TG and chylomicrons will contribute to the metabolic load experienced by the β cell. Intrapancreatic triglyceride content and lipid supply were decreased in both responders and non-responders.

**β Cell Function**

Fasting plasma insulin decreased in both groups during weight loss (responders, 108.3 ± 10.0 to 38.7 ± 4.4 pmol/L, p < 0.0001; non-responders, 77.2 ± 8.5 to 35.5 ± 5.3 pmol/L, p = 0.0002; Figure 4F). Because of the higher baseline level in responders, there was a greater decrease in this group (−69.7 ± 9.3 versus −41.7 ± 5.8 pmol/L, p < 0.01). At 12 months, fasting plasma insulin remained steady in both groups (responders, 41.1 ± 5.5 pmol/L, p = 0.41; non-responders, 45.8 ± 8.4 pmol/L, p = 0.40).

First-phase insulin secretion increased in responders after weight loss from 0.04[0.00–0.05] to 0.11[0.0005–0.51] nmol/min/m² (p < 0.0001), whereas no change was observed in the non-responders (0.02[0.07–0.13] to 0.01[0.04–0.05] nmol/min/m², p = 0.96; Figure 5A; Table 2). In the responders, increased first-phase insulin secretion was maintained during the weight maintenance phase (to 0.11[0.005–0.81] nmol/min/m², p = 0.97). Between baseline and 12 months the change was highly significant (p = 0.0001).

There was a gradual increase in maximal insulin secretion in responders after weight loss that became significant at 12 months (0.62[0.13–1.95] to 0.94[0.25–2.69] nmol/min/m², p < 0.04 compared with baseline; Figure 5B). It remained unchanged in non-responders.

First-phase and total insulin secretion rates remained unchanged in the control group throughout the study (Table S1).

It was established many years ago that chronic in vitro exposure of β cells to triglyceride or fatty acids decreases ability to respond to an acute increase in glucose levels (Lee et al., 1994), and the concept that excess fat can impair β cell function is not new (McGarry, 2002; Unger, 1995). In the ZDF rat, the onset of hyperglycemia is preceded by a rapid increase in...
pancreatic fat (Lee et al., 1994), and diabetes is completely preventable by restriction of food intake (Onohda et al., 1995). Chronic exposure of human β cells to lipid excess brings about decreased function (Zhou and Grill, 1995). Early studies demonstrated the ultrastructural damage brought about even by relatively low concentrations of saturated fatty acids (Pinnick et al., 2008, 2010), and this ER stress has been identified in other in vivo studies of type 2 diabetes (Huang et al., 2007; Laybutt et al., 2007). Clearly, hyperglycemia cannot explain the initiation of β cell stress in type 2 diabetes, but once the increased glucose levels are added to lipid-induced stress the increased glucose supply will compound and perpetuate the metabolic insult (Bensellam et al., 2012; Poitout et al., 2010; Weir et al., 2013). Loss of fully differentiated β cell phenotype is now recognized as the most likely mechanism underlying type 2 diabetes (Bensellam et al., 2018; Brereton et al., 2014; Spijker et al., 2015; Talchai et al., 2012; Wang et al., 2014; White et al., 2013). Very recent work has identified markers of dedifferentiation in the islets from people with type 2 diabetes (Cinti et al., 2016). In the non-responders, lower baseline fasting plasma insulin levels, lower ALT levels, and higher HbA1c are consistent with a more advanced, irreversible stage of β cell dysfunction.

A potential alternative explanation could be that the non-responders have a different etiology of diabetes, in which non-lipid-driven defects in β cells are more important. However, the responders and non-responders were similar in anthropological characteristics at baseline, and exhibited the same abnormalities of grossly elevated liver fat content and all other metabolic abnormalities. Even though the DIRECT cohort was selected to have duration of type 2 diabetes of less than 6 years, the non-responders had a modestly longer recorded duration of disease. It is established that the natural history of β cell decline follows widely different time courses between individuals (Harrison et al., 2012; Turner et al., 1999), but this is the first time that a difference in disease duration has been shown to relate to the capacity for re-differentiation during the first 6 years of type 2 diabetes. This observation carries potentially important implications for the initial clinical approach to management. At present, the early management of type 2 diabetes tends to involve a period of adjusting to the diagnosis plus pharmacotherapy with lifestyle changes, which in practice are modest. The present data suggest that substantial weight loss at the time of diagnosis may be more appropriate to prevent ongoing loss of β cell capacity.

Substrate Oxidation

The return to non-diabetic glucose control was accompanied by an increase in basal glucose oxidation rates and a fall in basal lipid oxidation rates (Table 1). These changes were not fully developed immediately after weight loss, but maximal at 12 months. The glucose oxidation rates in responders increased from 1.27 ± 0.12 at baseline to 1.44 ± 0.14 and to 2.00 ± 0.19 mg/kg/min after weight loss and weight maintenance, respectively (p < 0.0001 between baseline and 12 months). This was reflected in a greater increase in responders between baseline and 12 months compared with non-responders (0.75 ± 0.18 versus 0.11 ± 0.23 mg/kg/min, p = 0.006; Table 2). Conversely, lipid oxidation rates decreased in responders from 0.96 ± 0.05 to 0.87 ± 0.06 (p = 0.28) and to 0.64 ± 0.09 mg/kg/min (p < 0.0001), with a greater decrease than in non-responders over the same period (−0.32 ± 0.08 versus −0.05 ± 0.09 mg/kg/min, p < 0.04). There were no significant changes in substrate oxidation rates in the non-responders (Table 1).

Limitations of Study

Reflecting the population of Tyneside, 98% of participants were white, and comparable studies in other ethnic groups are required. However, socio-economic deprivation was well represented, with 39% being from the lowest two quintiles for deprivation (Taylor et al., 2017). At baseline, participants were taking
a range of anti-diabetic medications, reflective of current practice. Although people on insulin therapy were excluded from this primary care-based study for practical reasons, prior insulin therapy is not a major determinant of diabetes remission following major weight loss (Panunzi et al., 2016). The study participants were not followed closely in a specialist center, but lived normal lives, and reviewed by different primary care nurse, possibly introducing some heterogeneity. This could be interpreted to indicate generalizability of the conclusions. Finally, the observations relate to only 12 months of observation, and a 24-month follow-up is underway (Taylor et al., 2017).

**Conclusions**

This study demonstrates the physiologic changes associated with the return to normal glucose homeostasis in type 2 diabetes. It also quantifies the responses to weight loss in those who returned to normal glucose control compared with those who did not, and shows most marked differences between these two groups to be in their ability to recover first-phase insulin response. An average decrease in body weight of 15% was achieved by a structured program delivered by primary care staff. This brought about profound changes in lipid metabolism, irrespective of response in terms of glucose control. The greatest change was in liver fat content, which fell from high levels to normal in the whole intervention group at 12 months. Fall in plasma levels of VLDL1-TG was accompanied by fall in intrapancreatic fat content. All changes in lipid metabolism and intra-organ lipid remained steady over 12 months if weight loss was maintained, but, critically, only the responders demonstrated early and sustained improvement in β cell function as measured by gold standard methodology, with the difference at 12 months being striking. In summary, weight loss in early type 2 diabetes brings about similar correction of intra-organ fat content in all, but the defect in those who do not return to non-diabetic glucose control appears intrinsic to the β cell.

**STAR METHODS**

Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
- **CONTACT FOR REAGENT AND RESOURCE SHARING**
We are grateful to Louise Ward, Tim Hodgson, and Dorothy Wallace, research radiographers; Helen Pilkington, research nurse; Susan McLeilen, Alison Younghusband, Louise Burnip, Marie Appleton, and Paul Welsh, biochemists; and Wilma Leslie, Trial Coordinator, for invaluable assistance. The study was funded by a grant from Diabetes UK (award number 13/0004691). The formula

\[
\text{ACKNOWLEDGMENTS}
\]

We are grateful to Louise Ward, Tim Hodgson, and Dorothy Wallace, research radiographers; Helen Pilkington, research nurse; Susan McLeilen, Alison Younghusband, Louise Burnip, Marie Appleton, and Paul Welsh, biochemists; and Wilma Leslie, Trial Coordinator, for invaluable assistance. The study was funded by a grant from Diabetes UK (award number 13/0004691). The formula

\[
\text{SUPPLEMENTAL INFORMATION}
\]

Supplemental Information includes one table and can be found with this article online at https://doi.org/10.1016/j.cmet.2018.07.003.

\[
\text{REFERENCES}
\]


## STAR★METHODS

### KEY RESOURCES TABLE

<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Chemicals, Peptides, and Recombinant Proteins</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sodium Chloride</td>
<td>Sigma-Aldrich, UK</td>
<td>Cat No: S9888</td>
</tr>
<tr>
<td>Sodium Bromide 97%</td>
<td>Alfa Aesar, USA</td>
<td>Cat No: 14037</td>
</tr>
<tr>
<td>Na₂ EDTA</td>
<td>VWR International Ltd, UK</td>
<td>Cat No: 100935V</td>
</tr>
<tr>
<td>Sodium Hydroxide</td>
<td>VWR International Ltd, UK</td>
<td>Cat No: 102525P</td>
</tr>
<tr>
<td>Ultracentrifuge tubes</td>
<td>SETON SCIENTIFIC, USA</td>
<td>Cat No: 7031W</td>
</tr>
<tr>
<td>Glass Pasteur Pipettes</td>
<td>VWR International Ltd, UK</td>
<td>Cat No: VWRI 1822</td>
</tr>
<tr>
<td>0.9% Sodium Chloride</td>
<td>Fresenius Kabi Ltd, UK</td>
<td>Freeflex</td>
</tr>
<tr>
<td>Intralipid 20%</td>
<td>Fresenius Kabi Ltd, UK</td>
<td>Intralipid 20%</td>
</tr>
<tr>
<td>Intralipid 10%</td>
<td>Fresenius Kabi Ltd, UK</td>
<td>Intralipid 10%</td>
</tr>
<tr>
<td>20% Dextrose</td>
<td>Fresenius Kabi Ltd, UK</td>
<td>20% Dextrose</td>
</tr>
<tr>
<td>Arginine</td>
<td>Martindale Pharmaceuticals, UK</td>
<td>L-Arginine hydrochloride (50%)</td>
</tr>
<tr>
<td><strong>Critical Commercial Assays</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Triglyceride</td>
<td>Roche Diagnostics, UK</td>
<td>Cat No: 05171407 190</td>
</tr>
<tr>
<td>Insulin ELISA kit</td>
<td>Mercodia AB, Sweden</td>
<td>10-1128-01</td>
</tr>
<tr>
<td>C-peptide ELISA kit</td>
<td>Mercodia AB, Sweden</td>
<td>10-1136-01</td>
</tr>
<tr>
<td>HbA1c</td>
<td>Tosoh Bioscience, UK</td>
<td>HPLC-923G8</td>
</tr>
<tr>
<td>NEFA enzymatic calorimetric kit</td>
<td>BMG labtech, Germany</td>
<td>FLUOstar Omega microplate reader</td>
</tr>
<tr>
<td>Ketone meter</td>
<td>Abbott Diabetes Care Ltd, UK</td>
<td>Optium Xceed (XCF644-3826)</td>
</tr>
<tr>
<td><strong>Deposited data</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Raw data</td>
<td>Mendeley dataset</td>
<td><a href="https://doi.org/10.17632/9k9cgb8mwy.1">https://doi.org/10.17632/9k9cgb8mwy.1</a></td>
</tr>
<tr>
<td><strong>Software and Algorithms</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3T Philips Achieva scanner</td>
<td>Philips, Netherlands</td>
<td>SN: 17497</td>
</tr>
<tr>
<td>Six-channel cardiac array</td>
<td>Philips, Netherlands</td>
<td>PN: 453567009711</td>
</tr>
<tr>
<td>Three-point Dixon acquisition</td>
<td>Philips, Netherlands</td>
<td>mDixon</td>
</tr>
<tr>
<td>Balanced Turbo Field Echo acquisition</td>
<td>Philips, Netherlands</td>
<td>BTFE</td>
</tr>
<tr>
<td>Glucose analyzer</td>
<td>Yellow Springs, USA</td>
<td>YSI 2300 STAT Plus</td>
</tr>
<tr>
<td>Quark RMR</td>
<td>COSMED, Italy</td>
<td>PN:C09074-01-99</td>
</tr>
<tr>
<td>MATLAB</td>
<td>MathWorks, UK</td>
<td>RRID: SCR_001622; Version R2013a</td>
</tr>
<tr>
<td>ImageJ</td>
<td>National Institutes of Health (NIH), USA</td>
<td>RRID: SCR_003070; Version 1.50</td>
</tr>
<tr>
<td>Minitab</td>
<td>Minitab, USA</td>
<td>RRID: SCR_014483; Version 17</td>
</tr>
<tr>
<td>MRicro</td>
<td>University of South Carolina, USA</td>
<td>RRID: SCR_008264; Version 1.40</td>
</tr>
<tr>
<td><strong>Other</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liquid formula diet (825–853 kcal/day)</td>
<td>Cambridge Weight Plan Ltd., UK</td>
<td>N/A</td>
</tr>
</tbody>
</table>

## CONTACT FOR REAGENT AND RESOURCE SHARING

Further information and requests for reagents may be directed to and will be fulfilled by the Lead Contact, Roy Taylor (roy.taylor@ncl.ac.uk).

## EXPERIMENTAL MODEL AND SUBJECT DETAILS

The metabolic study was nested within the cluster-randomised controlled Diabetes Remission Clinical Trial (DiRECT; ISRCTN03267836) (Leslie et al., 2016). Ethical approval was obtained from the West of Scotland Ethics Committee, and written informed consent was obtained from all participants. The primary aim of DiRECT was to assess the effect of weight loss by low calorie diet on type 2 diabetes remission in a routine primary care setting. Individuals with type 2 diabetes living in the Tyneside region of...
England (n=90, 38F/52M, (mean± SD): age 52.8±7.9 years, weight 100.2±16.3kg, BMI 34.7±7.4 kg/m², diabetes duration 3.0±1.7 years, HbA1c 7.5±1.0 %) were recruited by their general practices (Figure 2). Inclusion criteria were diabetes duration of <6 years, age between 20-65 years, HbA1c ≥ 6.5 % (≥6.1% if taking anti-diabetes agents), and BMI of 27-45kg/m². Subjects were not recruited if pregnant, experienced weight loss of more than 5kg within the past 6 months or they have serious health problems. The majority of participants were white European with <2% of other ethnic minorities including Black African and South Asian. Most participants were on glucose lowering medication. Baseline characteristics of the whole DiRECT cohort have been described (Taylor et al., 2017) and the baseline anthropometric, clinical and metabolic features for geographically defined subgroup who underwent detailed physiologic study are presented in Table 1.

GP practices were randomized to either Intervention or Control groups. Intervention group subjects stopped all anti-diabetic medication on day 1 of the Counterweight Plus weight management programme consisting of 825–853 kcal/d liquid formula diet (Cambridge Weight Plan Ltd., UK) continued for 12-20 weeks, followed by a 2-6 week food reintroduction phase, then ongoing support for weight maintenance. The Control group continued usual diabetes management by their GP practice according to current UK clinical guidelines.

The Tyneside cohort was designed to further study metabolic changes occurring during weight loss and remission of diabetes (Figure 1). Intervention group subjects were classified as responder or non-responder at the end of each phase. Responders were defined as those achieving non-diabetic levels of Hba1c (<6.5%) and blood glucose (<126mg/dl) off any anti-diabetes medication for at least 2 months. The purpose of the Control group was to examine sequential changes over the time course of the study in type 2 diabetic subjects, and participants (n=2) who lost >5kg weight and became non-diabetic were excluded from the analysis. All studies were performed after an overnight fast, and subjects drove or were transported to the MR Centre by taxi to minimise variability of physical activity and stress of travel.

**METHOD DETAILS**

**Intraorgan Fat Quantification**
All participants underwent Magnetic Resonance (MR) quantification of pancreatic and hepatic fat on three occasions: at baseline, following return to isocaloric eating after weight loss and at 12 months (Figure 1). MR data were acquired using a 3T Philips Achieva scanner with six-channel cardiac array (Philips, Netherlands). Data were acquired by three-point Dixon method, with gradient-echo scans acquired during one breath hold (Al-Mrabeh et al., 2017). Hepatic fat content was measured by selecting homogenous regions of interest on five image slices of liver (Lim et al., 2011). Intrapancreatic fat content was quantified using the MR-opsys method optimized to exclude interlobular adipose tissue areas (Al-Mrabeh et al., 2017). Analysis of pancreas fat was carried out by a single observer (AAM) in a blinded manner.

**Lipoprotein Separation and VLDL1-TG Production**
VLDL1-triglyceride levels were determined from fasting plasma samples taken at each time point. Briefly, the VLDL1-triglyceride production rate was measured by accumulation of plasma VLDL1-triglyceride during competitive blockade of lipoprotein lipase by excess Intralipid (Al-Shayji et al., 2007). To do so, 20% Intralipid (Fresenius Kabi Ltd, UK) was injected intravenously as a bolus (0.1 g/kg body mass) followed by continuous infusion of 10% Intralipid at 0.1 g/kg/h by infusion pump (Arcomed Infusion Ltd, UK). Plasma samples were collected at six points over 75 min. After two step centrifugation, to remove blood cells then chylomicrons plus Intralipid particles (Scientific Laboratory Supplies Ltd, UK), the VLDL1 fraction was separated by ultracentrifugation at 278,000g for 98 minutes using the SW 40 Ti swinging-bucket rotor (Beckman Coulter, USA). Triglyceride concentration of this fraction was quantified using the standard method (Roche Diagnostics, UK), and VLDL1-triglyceride production rates were calculated from the gradient of the linear increase in plasma concentration over time.

**Beta Cell Function**
A Stepped Insulin Secretion Test with Arginine stimulation (SISTA) was used to quantitate first phase insulin secretion and maximal rate of insulin secretion (Lim et al., 2011; Toschi et al., 2002). Square wave hyperglycemia (50.4 then 100.8 mg/dl above baseline) was achieved by bolus of 20% Dextrose (Fresenius Kabi Ltd, UK) followed by variable 20% Dextrose infusion for each 30 minute step using an infusion pump (Arcomedical Infusion Ltd, UK). An arginine bolus of 5g L-Arginine hydrochloride 50% (Martindale Pharmaceuticals, UK) was diluted in 10 ml of 0.9% sodium chloride (Fresenius Kabi Ltd, UK), and injected during the second step of hyperglycemia to assess maximal insulin secretory capacity, followed by sampling every 2 min for 10 min. Blood samples for determination of C-peptide concentrations were obtained every 2 min for the first 10 min of each step, then every 5 min. Insulin secretion rates were calculated using a deconvolution method, modelling C-peptide kinetics (Lim et al., 2011).

**Indirect Calorimetry**
Indirect calorimetry was carried out in the fasting state after 30 min of supine rest using a Quark ventilated hood calorimeter (COSMED, Italy). Substrate oxidation was calculated using standard equations (Frayn, 1983).
Analytical Procedures
Glucose was measured by the oxidase method (Yellow Springs, USA). HbA1c was quantified using HPLC (Tosoh Bioscience, UK). Liver function tests were analysed by standard methods at the Institute of Cardiovascular and Medical Sciences, University of Glasgow. C-peptide, insulin, glucose, NEFA, VLDL1-triglyceride, ketones and other metabolites were analysed at Clinical Pathology Accreditation Laboratory (Newcastle upon Tyne Hospital NHS Foundation Trust, UK) using standard kits as described in the Key Resources Table.

QUANTIFICATION AND STATISTICAL ANALYSIS
Analyses were conducted on all subjects with paired data both before and after weight loss and weight maintenance phases. Data are presented as mean±SEM for normally distributed data and median (range) for skewed data as stated in the Figure legends and main text. Student paired or two-sample t test was used as appropriate for parametric data and Mann Whitney U test for nonparametric data. All statistical analyses including testing the normality of data distribution were performed using Minitab 17 (Minitab, USA) and a P value <0.05 was considered as significant. Paired data were presented in all tables, and the number of subjects in each group is stated in the column headings of each Table. We excluded from the analysis 6 subjects (2 controls who lost weight and became non-diabetic, and 4 intervention participants who changed responder status between 5 and 12 months).

The study was designed to compare change in parameters between responders and non-responders, assuming a 60% rate of return to non-diabetic glucose control and a 25% loss to follow up. It was powered on the most stringent variable (change in pancreas fat) in responders compared with non-responders. The calculated sample size was achieved by randomising a greater proportion of general practices to Intervention in the Tyneside region. As there was 69% remission of diabetes after weight loss and 64% at 12 months, the above assumptions for statistical analysis were satisfied.

DATA AND SOFTWARE AVAILABILITY
The dataset of this study is available in Mendeley Data (https://doi.org/10.17632/9k9cgb8mwy.1).